FDA Approved: VYVGART HYTRULO — Supplemental Application (argenx US)

View source ↗

Summary

FDA approved a supplemental application for Vyvgart Hytrulo, the fixed-dose combination of efgartigimod alfa and hyaluronidase (human recombinant). The approval…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT))

Snippet

SUPPL AP for VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT))